Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical outcomes of direct-acting oral anticoagulants compared to warfarin in patients with non-valvular atrial fibrillation

비판막성심방세동 환자에서 직접작용 경구용 항응고제 임상적 효과와 부작용 연구

  • Received : 2021.12.09
  • Accepted : 2022.03.21
  • Published : 2022.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Non-valvular atrial fibrillation (NVAF) is associated with ischemic stroke risk in the aging population. Observational studies have indicated beneficial effects of direct-acting oral anticoagulant (DOAC) against ischemic stroke compared to warfarin. This study aimed to investigate ischemic stroke incidence and bleeding risk in patients on DOAC therapy. Methods: Using the database of Korean Health Insurance Review and Assessment-Aged Patient Sample 2015, we conducted a retrospective cohort study. Study subjects with NVAF diagnosis and prescribed anticoagulants were enrolled. Propensity score (PS) matching by age, sex, comorbidities, and medications were used. The clinical outcomes were major adverse cerebro-cardiovascular events (MACCEs, ischemic stroke/systemic embolism, myocardial infarction, cardiac death) and bleeding events. A cox proportional hazard model analysis was performed to compare the outcomes with hazard ratio (HR) and 95% confidence interval (CI). Results: Total 4,773 elderly patients with NVAF were initially included. Four PS-matched groups including rivaroxaban vs. warfarin-only (n=1,079), dabigatran vs. warfarin-only (n=721), rivaroxaban vs. dabigatran (n=721), and switchers of warfarin to rivaroxaban vs. warfarin-only (n=287) were analyzed. Every group showed statistically similar results of MACCEs and bleeding events, except for the group of rivaroxaban vs. dabigatran. Rivaroxaban users showed higher risks of bleeding events than dabigatran users (HR 2.25, 95% CI 1.01-4.99). Conclusion: In the elderly patients with NVAF, efficacy and safety outcomes among oral anticoagulants including DOACs and warfarin were similar, while rivaroxaban are more likely to have higher bleeding risks than dabigatran. Further research using large size sample is needed.

Keywords

Acknowledgement

본 연구는 2021년 식품의약품안전처의 연구과제(21153MFDS602) 수행하였습니다.

References

  1. Norby FL, Bengtson LG, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 2017;17(1):238. https://doi.org/10.1186/s12872-017-0672-5
  2. Bengtson LG, Lutsey PL, Chen LY, MacLehose RF, Alonso A. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. J Cardiol 2017;69(6):868-76. https://doi.org/10.1016/j.jjcc.2016.08.010
  3. Escobar C, Borras X, Bover Freire R, et al. A Delphi consensus on the management of oral anticoagulation in patients with non-valvular atrial fibrillation in Spain: ACOPREFERENCE study. PloS one 2020;15(6):e0231565. https://doi.org/10.1371/journal.pone.0231565
  4. Hill NR, Sandler B, Bergrath E, et al. A systematic review of network meta-analyses and real-world evidence comparing apixaban and rivaroxaban in nonvalvular atrial fibrillation. Clin Appl Thromb Hemost 2020;26:1076029619898764.
  5. Ko Y, Kim S, Park K, et al. Impact of the health insurance coverage policy on oral anticoagulant prescription among patients with atrial fibrillation in Korea from 2014 to 2016. J Korean Med Sci 2018;33(23):e163. https://doi.org/10.3346/jkms.2018.33.e163
  6. Lee I, Kim H, Je NK. Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea. J Cardiol 2015;66(6):475-81. https://doi.org/10.1016/j.jjcc.2015.06.013
  7. Han S, Jeong HS, Kim H Suh HS. The treatment pattern and adherence to direct oral anticoagulants in patients with atrial fibrillation aged over 65. PloS One 2019;14(4):e0214666. https://doi.org/10.1371/journal.pone.0214666
  8. Chen A, Stecker E, A Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 2020;9(13):e017559. https://doi.org/10.1161/JAHA.120.017559
  9. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019;74(1):104-32. https://doi.org/10.1016/j.jacc.2019.01.011
  10. Sanchez MA, Martinez VB, Ortiz MR, et al. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study. Rev Esp Cardiol (Engl Ed) 2020;73(1):14-20. https://doi.org/10.1016/j.recesp.2019.02.003
  11. Anghel L, Sascau R, Trifan A, Zota IM, Statescu C. Non-vitamin K antagonist oral anticoagulants and the gastrointestinal bleeding risk in real-world studies. J Clin Med 2020;9(5):1398. https://doi.org/10.3390/jcm9051398
  12. Lip GY, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. Stroke 2018;49(12):2933-44. https://doi.org/10.1161/STROKEAHA.118.020232
  13. Rutherford OW, Jonasson C, Ghanima W, Soderdahl F, Halvorsen S. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2020;6(2):75-85. https://doi.org/10.1093/ehjcvp/pvz086
  14. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. https://doi.org/10.1056/NEJMoa1009638
  15. Kim YH, Shim J, Tsai C, et al. A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. J Arrhythm 2018;34(4):418-27. https://doi.org/10.1002/joa3.12073
  16. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37(14):1145-53. https://doi.org/10.1093/eurheartj/ehv466
  17. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51. https://doi.org/10.1056/NEJMoa0905561
  18. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110(3):453-60. https://doi.org/10.1016/j.amjcard.2012.03.049
  19. Peter AN, Xiaoxi Y, Neena SA, Lindsey RS, Robert DM, Nilay DS. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest 2016;150(6):1302-12. https://doi.org/10.1016/j.chest.2016.07.013